Pediatric Radiology

, Volume 43, Issue 4, pp 418–427

Nuclear medicine and multimodality imaging of pediatric neuroblastoma

Authors

    • Department of Nuclear MedicineLudwig-Maximilians-University of Munich
  • Eva Coppenrath
    • Department of RadiologyLudwig-Maximilians-University of Munich
  • Thomas Pfluger
    • Department of Nuclear MedicineLudwig-Maximilians-University of Munich
Review

DOI: 10.1007/s00247-012-2512-1

Cite this article as:
Mueller, W.P., Coppenrath, E. & Pfluger, T. Pediatr Radiol (2013) 43: 418. doi:10.1007/s00247-012-2512-1

Abstract

Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system and is metastatic or high risk for relapse in nearly 50% of cases. Therefore, exact staging with radiological and nuclear medicine imaging methods is crucial for defining the adequate therapeutic choice. Tumor cells express the norepinephrine transporter, which makes metaiodobenzylguanidine (MIBG), an analogue of norepinephrine, an ideal tumor specific agent for imaging. MIBG imaging has several disadvantages, such as limited spatial resolution, limited sensitivity in small lesions and the need for two or even more acquisition sessions. Most of these limitations can be overcome with positron emission tomography (PET) using [F-18]2-fluoro-2-deoxyglucose [FDG]. Furthermore, new tracers, such as fluorodopa or somatostatin receptor agonists, have been tested for imaging neuroblastoma recently. However, MIBG scintigraphy and PET alone are not sufficient for operative or biopsy planning. In this regard, a combination with morphological imaging is indispensable. This article will discuss strategies for primary and follow-up diagnosis in neuroblastoma using different nuclear medicine and radiological imaging methods as well as multimodality imaging.

Keywords

NeuroblastomaDiagnosisIodobenzylguanidineScintigraphyPositron emission tomographyMultimodality imagingChild

Copyright information

© Springer-Verlag 2012